SHREWSBURY, Mass., Dec. 1 /PRNewswire-FirstCall/ -- TranXenoGen, Inc. ("TranXenoGen") announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application relating to the genetic engineering of male germ cells for the production of transgenic animals. This Notice constitutes acceptance of the application and indicates impending issuance of the patent.
The Company is developing the technology, known as Gene-Testes Transfection, as an alternative method for the production of high value transgenic animals that is applicable to many species. The technique involves the introduction of a gene into the germ cells of the testes, which would then produce sperm containing the transgene. Consequently, breeding of the male would result in the transmission of the gene to the next generation and the production of a transgenic animal.
TranXenoGen intends to out-license the technology as well as utilizing it for its own applications in therapeutic protein manufacturing.
TranXenoGen, Inc. Tel: 001 508 936 4214
George Uveges, President and CEO Email: firstname.lastname@example.org
College Hill Associates Tel: +44 (0) 7457 2020
TranXenoGen, Inc. (symbol TXN.L) is a publicly traded biotechnology company. Its shares are quoted on the Alternative Investment Market of the London Stock Exchange. The Company is developing avian transgenic technologies for the production of high volume therapeutic proteins. TranXenoGen is a development stage company and, as such, investors should be aware that an investment in the Company involves a substantially high degree of risk.
Risk Warning Notice:
This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.
CONTACT: George Uveges, President and CEO of TranXenoGen, Inc., 001 508936 4214, email@example.com; or Nicholas Nelson of College HillAssociates, +44 (0) 7457 2020